Acorn Biolabs
Seed Round in 2019
Acorn Biolabs, Inc. is a biotechnology company based in Toronto, Canada, founded in 2017. The company specializes in providing a take-home human cell cryopreservation service that focuses on non-invasive, follicle-based cell collection methods. Acorn Biolabs aims to preserve healthy young cells for potential future use in regenerative treatments, including gene therapies and stem cell therapeutics. Its services are accessible directly to consumers through both at-home and in-clinic collections, and the company partners with various clinics and pharmacies to expand its reach across Canada.
ThoughtWire
Series A in 2018
ThoughtWire is a developer of digital twin technology focused on enhancing the efficiency and safety of hospitals, commercial buildings, and cities. Its flagship platform, ThoughtWireOS, integrates data from people, processes, and the physical environment to create smarter spaces. By leveraging this data along with insights from Internet of Things (IoT) devices, ThoughtWire's applications offer real-time guidance and automation for various stakeholders, including clinicians, patients, office workers, and first responders. The company's software solutions aim to unlock the potential of built environments by ensuring energy efficiency, improving operational safety, and enabling proactive issue resolution. Through its innovative approach, ThoughtWire contributes to the development of self-optimizing systems that enhance the overall quality of life in urban settings and workplaces.
Muse has developed brainwave-controlled computing technology and applications that converts brainwaves into digital signals. They have created a hardware and software platform technology that converts brainwaves into digital signals that are fed into a computer. InteraXon then provides consumers with applications that use these brainwaves to perform activities such as meditation, gaming, ADHD assistance, and many others to come. The company was founded in 2007 and is headquartered in Toronto, Ontario.
Cyclica Inc. is a Toronto-based company that specializes in enhancing the drug discovery process through its integrated cloud-based platform, which leverages artificial intelligence and biophysics. The company offers two main technologies: Ligand Design, which generates novel molecules and filters them based on various properties, and Ligand Express, a platform that screens small-molecule drugs against structurally-characterized protein repositories to assess poly-pharmacological profiles. This innovative approach allows pharmaceutical scientists to identify potential ligand-protein interactions, prioritize lead candidates, and explore opportunities for drug repurposing while also understanding potential adverse effects. Cyclica has established a strategic partnership with AUM Biosciences and has been operational since its incorporation in 2010.
Circle Cardiovascular Imaging
Venture Round in 2016
Circle Cardiovascular Imaging is a Canadian company specializing in the development and marketing of advanced cardiovascular post-processing software designed for the evaluation of magnetic resonance imaging (MRI) and computed tomography (CT) images. Founded in 2007 and headquartered in Calgary, the company offers a suite of products including cmr42 and ct42 for analyzing cardiovascular MR and CT images, respectively, as well as cvi42, which integrates both modalities. Additionally, report42 facilitates the documentation and reporting of these images. The software supports medical professionals in diagnosing a range of cardiovascular conditions, such as heart failure, coronary artery disease, and myocarditis, among others. Circle Cardiovascular Imaging employs big data and deep learning technologies to enhance the accuracy and effectiveness of its analyses, serving healthcare institutions and physicians in both clinical and research environments. The company's solutions are distributed globally through a network of partners, and it also provides training and support services to ensure effective utilization of its software.
QoC Health
Seed Round in 2016
QoC Health Inc. is a Toronto-based company that specializes in developing a cloud-based digital platform aimed at enhancing patient engagement and improving healthcare outcomes. Founded in 2010, the company offers a range of solutions that facilitate patient monitoring, communication, and integration with existing medical records. Its flagship product, the Cloud Connect platform, enables healthcare providers to deploy tailored healthcare solutions for various scenarios, including post-discharge recovery monitoring, clinical research, and patient education. By connecting patients with healthcare providers, family, and peer support networks, QoC Health seeks to improve patient satisfaction, reduce readmissions, and lower overall healthcare costs. The platform is designed to simplify the implementation of compliant, connected technology solutions, thereby accelerating the delivery of advanced healthcare services across Canada.
Perimeter Medical Imaging AI
Series A in 2015
Perimeter Medical Imaging AI is a medical technology company focused on revolutionizing cancer surgery through the development of ultra-high-resolution, real-time imaging tools. These advanced imaging solutions are designed to address significant unmet medical needs in the surgical field, enhancing the ability to detect and delineate cancerous tissues during procedures. By improving the accuracy of surgical interventions, Perimeter aims to optimize patient outcomes and contribute to more effective cancer treatment strategies.
ChipCare Corporation, founded in 2009 and based in Toronto, Canada, specializes in developing point-of-care testing and monitoring systems for healthcare applications. The company aims to enhance access to advanced blood tests worldwide through its innovative handheld cell analyzer system, which can conduct multiple diagnostic tests from a single drop of blood. This includes cell counting, protein and enzyme analysis, and pathogen detection. ChipCare's solution integrates patient identification, blood testing, and quality management protocols, making it suitable for both resource-rich and resource-limited settings. The primary revenue stream is expected to come from the sale of disposable test slides, which are critical components of its diagnostic platform. This microfluidic technology enables healthcare providers to perform a variety of tests efficiently, facilitating timely diagnosis and treatment for patients in need.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.